Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Eli Lilly and Company: A Top Growth Stock to Buy on the Dip

November 15, 2024
Eli Lilly and Company (LLY) has recently been highlighted as one of the top growth stocks to invest in. Despite a recent dip in its stock price, experts believe this presents a great opportunity for investors. With its strong pipeline of innovative drugs, including potential breakthrough treatments for various diseases, Eli Lilly is well-positioned for long-term growth. Its low volatility also makes it an attractive option for risk-averse investors. To capitalize on this potential, it is recommended to seek the advice of professionals at Stocks Prognosis for an accurate forecast of Eli Lilly's stock movement.
If you want to leave a comment, then you need Login or Register





Other data for LLY

Related data

LLYAugust 12, 2025Eli Lilly and Co LLY Traded Lower in Q2 Despite Good Results  ~1 min.

Eli Lilly and Company, despite reporting good results in the second quarter of this year, saw its stock price traded lower....


LLYAugust 8, 2025ELI LILLY AND COMPANY Stock Hits Price Target Forecast with Profit of 18.31%  ~1 min.

ELI LILLY AND COMPANY stock has successfully achieved the price target forecast set by QuantWave with a profit of 18.31%. The forecast, which indicated a short position on June 4, 2025, at a price of 764....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Forecasted Price Target with 20.09% Profit: QuantWave Achieves Success  ~1 min.

On January 28, 2025, QuantWave, an automated forecasting platform, issued a short signal for ELI LILLY AND COMPANY stock when it was trading at 800.2 $....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits QuantWave Forecast, Delivering 19.57% Profit  ~1 min.

ELI LILLY AND COMPANY has achieved the price target forecast set by QuantWave, signaling a 19.57% profit for investors....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Price Target Forecast as QuantWave Users Gain 17.38% Profit  ~1 min.

ELI LILLY AND COMPANY stock recently achieved the price target forecast set by QuantWave, marking a significant success for users of the automated forecasting platform....


LLYAugust 7, 2025ELI LILLY AND COMPANY Hits Forecast Profit of 23.55%: A Success Story for QuantWave  ~2 min.

ELI LILLY AND COMPANY, a prominent player in the pharmaceutical industry, recently achieved a significant milestone by hitting a price target forecast generated by the innovative forecasting platform, QuantWave. The forecast, which indicated a short direction signal on April 17, 2025, at a price of 836.4 USD, proved to be accurate as the stock reached the predicted target price of 639.46 USD on Au...


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Forecast Price Target with 22.13% Profit - QuantWave Achieves Success in Stock Prediction  ~2 min.

ELI LILLY AND COMPANY stock recently reached the forecast price target set by QuantWave, resulting in a profit of 22.13%....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Price Target Forecast, Generating 17.25% Profit  ~1 min.

ELI LILLY AND COMPANY stock has successfully achieved the price target forecast set by QuantWave, reaching a profit of 17.25%. The forecast signal was issued on April 30, 2024, with the stock price at $772....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Short Price Target Forecast with 19.15% Profit  ~1 min.

On December 24, 2024, QuantWave, the automated forecasting platform, issued a short signal for ELI LILLY AND COMPANY stock when it was priced at 790.94 $....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Price Target Forecast with 22.51% Profit for QuantWave Users  ~2 min.

ELI LILLY AND COMPANY, a prominent pharmaceutical company, recently achieved the price target forecast set by QuantWave, an automated forecasting platform, resulting in a profitable outcome for investors. The forecast signal was generated on 8th November 2024 when the stock was priced at 825.23 $. The prediction indicated a short direction, and on 7th August 2025, the target price of 639.46 $ was ...


AZNJanuary 1, 2025New breakthrough in medical research announced by AstraZeneca PLC AZN  ~2 min.

Leading pharmaceutical company AstraZeneca PLC AZN has made a groundbreaking discovery in the field of medical research....


GSKJanuary 11, 2025Exciting Developments for GSK plc: Breakthrough Therapy Designation Granted for ADC  ~2 min.

GSK plc, a leading pharmaceutical company, has achieved a significant milestone in its journey towards developing breakthrough treatments....


GSKFebruary 25, 2025GlaxoSmithKline (GSK) Enhances Pipeline Plans with Breakthrough Treatment - Stocks Prognosis  ~3 min.

GlaxoSmithKline, commonly known as GSK, a leading global pharmaceutical company, has recently made significant progress in its pipeline plans by developing a breakthrough treatment for a life-threatening disease. The company's innovative research and development efforts have paid off, leading to the creation of a promising drug that could potentially revolutionize the healthcare industry. GSK's br...


AZNJanuary 2, 2025AstraZeneca PLC Announces Breakthrough in Cancer Treatment Research  ~2 min.

AstraZeneca PLC, a leading global pharmaceutical company, has reported a significant breakthrough in its cancer treatment research....


BMYDecember 19, 2024Bristol Myers Squibb Awards $25M Milestone Payment for Breakthrough ALS Treatment Target Discovery - Stock Prognosis Recommendation  ~1 min.

Bristol-Myers Squibb Company (BMY) recently awarded a milestone payment of $25 million for the discovery of a breakthrough treatment target for ALS (Amyotrophic lateral sclerosis), also known as Lou Gehrig's disease. The significant achievement was made possible through a collaboration with insitro, a leading precision medicine company. The selection of the first novel genetic target marks a major...